Literature DB >> 22379029

TGF-β-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts.

Noritoshi Honda1, Masatoshi Jinnin, Ikko Kajihara, Takamitsu Makino, Katsunari Makino, Shinichi Masuguchi, Satoshi Fukushima, Yoshinobu Okamoto, Minoru Hasegawa, Manabu Fujimoto, Hironobu Ihn.   

Abstract

Previous reports indicated the significance of the TGF-β signaling in the pathogenesis of systemic sclerosis. We tried to evaluate the possibility that microRNAs (miRNAs) play a part in the type I collagen upregulation seen in normal fibroblasts stimulated with exogenous TGF-β and systemic sclerosis (SSc) fibroblasts. miRNA expression profile was evaluated by miRNA PCR array and real-time PCR. The protein expression of type I collagen was determined by immunoblotting. In vivo detection of miRNA in paraffin section was performed by in situ hybridization. Several miRNAs were found to be downregulated in both TGF-β-stimulated normal fibroblasts and SSc fibroblasts compared with normal fibroblasts by PCR array. Among them, miR-196a expression was decreased in SSc both in vivo and in vitro by real-time PCR or in situ hybridization. In SSc fibroblasts, miR-196a expression was normalized by TGF-β small interfering RNA. miR-196a inhibitor leads to the overexpression of type I collagen in normal fibroblasts, whereas overexpression of the miRNA resulted in the downregulation of type I collagen in SSc fibroblasts. In addition, miR-196a was detectable and quantitative in the serum of SSc patients. Patients with lower serum miR-196a levels had significantly higher ratio of diffuse cutaneous SSc:limited cutaneous SSc, higher modified Rodnan total skin thickness score, and higher prevalence of pitting scars than those without. miR-196a may play some roles in the pathogenesis of SSc. Investigation of the regulatory mechanisms of type I collagen expression by miR-196a may lead to new treatments using miRNA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22379029     DOI: 10.4049/jimmunol.1100876

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

Review 1.  microRNA deregulation in keloids: an opportunity for clinical intervention?

Authors:  Xin Yu; Zheng Li; Matthew T V Chan; William K K Wu
Journal:  Cell Prolif       Date:  2015-10-21       Impact factor: 6.831

Review 2.  The role of microRNAs in skin fibrosis.

Authors:  Olubukola Babalola; Andrew Mamalis; Hadar Lev-Tov; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2013-11       Impact factor: 3.017

Review 3.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 4.  Epigenetics and systemic sclerosis.

Authors:  Nezam Altorok; Bashar Kahaleh
Journal:  Semin Immunopathol       Date:  2015-07-11       Impact factor: 9.623

5.  Astragalus polysaccharide suppresses excessive collagen accumulation in a murine model of bleomycin-induced scleroderma.

Authors:  Zhen-Feng Hao; You-Ming Su; Jing-Yang Liu; Cong-Min Wang; Rong-Ya Yang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 6.  Targeted therapies for systemic sclerosis.

Authors:  Christopher P Denton; Voon H Ong
Journal:  Nat Rev Rheumatol       Date:  2013-04-09       Impact factor: 20.543

7.  A TGFβ-miR-182-BRCA1 axis controls the mammary differentiation hierarchy.

Authors:  Haydeliz Martinez-Ruiz; Irineu Illa-Bochaca; Coral Omene; Douglas Hanniford; Qi Liu; Eva Hernando; Mary Helen Barcellos-Hoff
Journal:  Sci Signal       Date:  2016-12-06       Impact factor: 8.192

8.  Needle-Free Injection of Exosomes Derived from Human Dermal Fibroblast Spheroids Ameliorates Skin Photoaging.

Authors:  Shiqi Hu; Zhenhua Li; Jhon Cores; Ke Huang; Teng Su; Phuong-Uyen Dinh; Ke Cheng
Journal:  ACS Nano       Date:  2019-08-26       Impact factor: 15.881

Review 9.  Epigenetics in Non-tumor Immune-Mediated Skin Diseases.

Authors:  M C Ovejero-Benito; E Daudén; Alejandra Reolid; E Muñoz-Aceituno; F Abad-Santos
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

10.  MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor.

Authors:  Xiangguang Shi; Qingmei Liu; Na Li; Wenzhen Tu; Ruoyu Luo; Xueqian Mei; Yanyun Ma; Weihong Xu; Haiyan Chu; Shuai Jiang; Zhimin Du; Han Zhao; Liang Zhao; Li Jin; Wenyu Wu; Jiucun Wang
Journal:  Cell Cycle       Date:  2018-09-17       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.